(MENAFN- GlobeNewsWire - Nasdaq) Boost ROI by outsourcing preclinical testing to cut costs and timelines, while using AI, automation, in silico models and organ-on-chip platforms to improve accuracy.Dublin, Oct. 27, 2026 (GLOBE NEWSWIRE) -- "Preclinical Contract Research Organizations - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.
The global Preclinical Contract Research Organizations (CROs) market was valued at an estimated US$7.5 billion in 2024 and is projected to reach US$11.3 billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.0%. Growth is being supported by increased pharmaceutical and biotechnology research activity, rising drug development costs, greater outsourcing of preclinical services, and demand for specialized testing capabilities.
The comprehensive market report examines industry trends, growth drivers, competitive conditions, technology developments, regional opportunities, and forecasts through 2030. It also assesses global tariff developments and their potential effects on CRO supply chains, laboratory sourcing, operating costs, investment decisions, and geographic strategies.
Preclinical CRO Market Trends and Growth Drivers
Preclinical CROs provide toxicology testing, bioanalysis, drug metabolism and pharmacokinetics (DMPK), pharmacodynamics, safety pharmacology, compound management, chemistry, regulatory consulting, and related research services. Pharmaceutical and biotechnology companies increasingly rely on external providers to access specialized infrastructure, experienced scientific personnel, scalable capacity, and regulatory expertise while reducing capital requirements and accelerating development timelines.
Demand is also rising as drug pipelines shift toward biologics, gene therapies, cell-based treatments, precision medicine, and other advanced modalities. These programs require sophisticated capabilities in immunology, genetic profiling, bioinformatics, immunogenicity assessment, and advanced toxicology. CROs with relevant scientific expertise and Good Laboratory Practice-compliant facilities are positioned to benefit from this transition.
Small and emerging biotechnology companies remain significant users of outsourced preclinical services because they often lack the facilities and personnel required to complete complex studies internally. Large pharmaceutical companies are also expanding CRO partnerships to improve resource allocation, manage fluctuating workloads, and concentrate internal investment on discovery programs and later-stage clinical development.
Technology Innovation Reshaping Preclinical Research
Artificial intelligence, machine learning, in silico modeling, and simulation are improving compound selection, pharmacokinetic analysis, toxicity prediction, and study design. These technologies can help identify development risks earlier, prioritize viable candidates, and reduce dependence on resource-intensive testing.
High-throughput screening and laboratory automation are further improving speed, consistency, and data quality across large-scale studies. Advanced imaging systems, including positron emission tomography and magnetic resonance imaging, support detailed monitoring of biological responses in preclinical models.
Adoption of 3D cell cultures, organ-on-a-chip systems, and microfluidic platforms is also increasing. These models support more predictive assessments of drug efficacy and toxicity while responding to industry and regulatory efforts to reduce animal testing. Wider acceptance of alternative testing technologies is expected to create additional opportunities for CROs offering differentiated research platforms.
Market Dynamics and Outsourcing Outlook
Rising laboratory costs, stringent regulatory requirements, and pressure to shorten drug development cycles are accelerating preclinical outsourcing. CROs with multinational operations can help sponsors coordinate studies across jurisdictions, address regional compliance requirements, and support global development strategies.
Pharmaceutical industry consolidation and continued merger and acquisition activity are also influencing demand. Flexible CRO capacity allows drug developers to adapt quickly as pipelines, budgets, and research priorities change. Providers capable of delivering integrated services from discovery through early clinical development are expected to gain strategic importance.
Domain Expert Insights
The report tracks the expanding role of specialized preclinical testing in advanced therapy development, the adoption of predictive research technologies, and the effects of outsourcing on pharmaceutical research productivity. It also evaluates how tariff negotiations, sourcing disruptions, supply chain realignment, and economic uncertainty may affect regional investment and competitive positioning through 2030.
Segment and Regional Highlights
Toxicology Testing: The segment is projected to reach US$3.2 billion by 2030, advancing at a CAGR of 7.4%. Bioanalysis and DMPK Studies: The segment is forecast to expand at a CAGR of 7.7% during the analysis period. United States: The U.S. preclinical CRO market was valued at approximately US$2.1 billion in 2024. China: The market is projected to grow at a CAGR of 6.6% and reach US$1.8 billion by 2030. Additional Markets: The analysis covers Canada, Japan, France, Germany, Italy, the United Kingdom, the rest of Europe, Asia-Pacific, and the rest of the world.
Scope of the Preclinical CRO Market Report
Services: Toxicology testing, bioanalysis and DMPK studies, compound management, chemistry, safety pharmacology, and other services. End Users: Biopharmaceutical companies, government and academic institutes, and medical device companies. Forecast Period: Annual sales analysis and market forecasts from 2024 through 2030, supported by historical analysis beginning in 2015. Competitive Analysis: Market presence, strategic positioning, growth prospects, and geographic reach of leading industry participants.
Companies Featured
The report profiles 33 companies operating in the global preclinical Contract Research Organizations market. Featured participants include Envigo Corporation, Eurofins Scientific, ICON plc, Laboratory Corporation of America Holdings, Medpace, MPI Research, Parexel International Corporation, Pharmaceutical Product Development (PPD), PRA Health Sciences, and WuXi AppTec.
Trade, Tariff, and Economic Analysis
This edition incorporates global trade and economic developments available as of June 2025. Coverage includes tariff negotiations across more than 180 countries, sourcing disruption, supply chain turbulence, regional realignment, and updated analysis of U.S. tariff policies. Global and regional forecasts have been adjusted to reflect tariff exposure, structural changes in globalization, and prevailing economic uncertainty.
The report also evaluates innovation trends, competitive market shares, economic indicators, regional prospects, and the positioning of leading companies. Buyers receive a complimentary update incorporating finalized tariff effects, new trade agreements, revised projections, and expanded country-level analysis.
Key Questions Addressed
How will the global preclinical CRO market develop through 2030? Which technologies and outsourcing trends will have the greatest market impact? Which service and end-use segments offer the strongest growth potential? How will tariff developments and supply chain changes affect regional strategies? Which companies are best positioned to compete in the evolving preclinical research services market?
Key Attributes:
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment